However, a growing body of evidence indicates that receptors such as EGFR and Met receptor tyrosine kinases (RTKs) or β1-integrin can remain active within endosomes to provide spatially and temporally restricting signals that contribute to pathway-specific tumor progression16,17,34,42–44. The gene discussed is EGFR; the disease is neoplasm.